You just read:

Bayer's Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

News provided by

Bayer HealthCare

08 Apr, 2013, 02:30 ET